GSA Capital Partners LLP Lowers Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

GSA Capital Partners LLP reduced its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 24.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 255,032 shares of the biotechnology company’s stock after selling 81,645 shares during the quarter. GSA Capital Partners LLP’s holdings in Aclaris Therapeutics were worth $293,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Stonepine Capital Management LLC purchased a new stake in shares of Aclaris Therapeutics during the second quarter valued at $2,120,000. Trium Capital LLP bought a new stake in shares of Aclaris Therapeutics in the second quarter valued at about $2,081,000. Russell Investments Group Ltd. raised its holdings in shares of Aclaris Therapeutics by 5,265.1% in the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 61,602 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Aclaris Therapeutics by 1.9% in the second quarter. Millennium Management LLC now owns 3,336,850 shares of the biotechnology company’s stock valued at $3,671,000 after acquiring an additional 63,358 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Aclaris Therapeutics by 4.4% in the first quarter. Vanguard Group Inc. now owns 4,929,775 shares of the biotechnology company’s stock valued at $6,113,000 after acquiring an additional 207,418 shares in the last quarter. 98.34% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on ACRS shares. Leerink Partners upgraded Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $2.00 to $7.00 in a report on Tuesday. Leerink Partnrs upgraded Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday. StockNews.com upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 15th. HC Wainwright reiterated a “neutral” rating on shares of Aclaris Therapeutics in a report on Tuesday, September 17th. Finally, Piper Sandler upgraded shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $3.00 to $13.00 in a report on Monday, November 18th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.80.

Insider Activity

In related news, Director Anand Mehra acquired 666,666 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $1,499,998.50. Following the completion of the acquisition, the director now directly owns 710,030 shares in the company, valued at $1,597,567.50. The trade was a 1,537.37 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 6.40% of the company’s stock.

Aclaris Therapeutics Stock Performance

Shares of Aclaris Therapeutics stock opened at $3.80 on Friday. The company has a market capitalization of $271.44 million, a PE ratio of -7.31 and a beta of 0.10. The company has a 50-day simple moving average of $1.77 and a two-hundred day simple moving average of $1.39. Aclaris Therapeutics, Inc. has a one year low of $0.77 and a one year high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.03). Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. The company had revenue of $4.35 million for the quarter, compared to analyst estimates of $8.31 million. On average, equities analysts predict that Aclaris Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.